Cargando…

Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value

Alzheimer's disease (AD) is an age-associated neurodegenerative disease characterized by the progressive loss of cognitive function, loss of memory and insomnia, and abnormal behavioral signs and symptoms. Among the various theories that have been put forth to explain the pathophysiology of AD,...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivasan, Venkatramanujam, Kaur, Charanjit, Pandi-Perumal, Seithikurippu, Brown, Gregory M., Cardinali, Daniel P.
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004402/
https://www.ncbi.nlm.nih.gov/pubmed/21197086
http://dx.doi.org/10.4061/2011/741974
_version_ 1782193975971545088
author Srinivasan, Venkatramanujam
Kaur, Charanjit
Pandi-Perumal, Seithikurippu
Brown, Gregory M.
Cardinali, Daniel P.
author_facet Srinivasan, Venkatramanujam
Kaur, Charanjit
Pandi-Perumal, Seithikurippu
Brown, Gregory M.
Cardinali, Daniel P.
author_sort Srinivasan, Venkatramanujam
collection PubMed
description Alzheimer's disease (AD) is an age-associated neurodegenerative disease characterized by the progressive loss of cognitive function, loss of memory and insomnia, and abnormal behavioral signs and symptoms. Among the various theories that have been put forth to explain the pathophysiology of AD, the oxidative stress induced by amyloid β-protein (Aβ) deposition has received great attention. Studies undertaken on postmortem brain samples of AD patients have consistently shown extensive lipid, protein, and DNA oxidation. Presence of abnormal tau protein, mitochondrial dysfunction, and protein hyperphosphorylation all have been demonstrated in neural tissues of AD patients. Moreover, AD patients exhibit severe sleep/wake disturbances and insomnia and these are associated with more rapid cognitive decline and memory impairment. On this basis, the successful management of AD patients requires an ideal drug that besides antagonizing Aβ-induced neurotoxicity could also correct the disturbed sleep-wake rhythm and improve sleep quality. Melatonin is an effective chronobiotic agent and has significant neuroprotective properties preventing Aβ-induced neurotoxic effects in a number of animal experimental models. Since melatonin levels in AD patients are greatly reduced, melatonin replacement has the potential value to be used as a therapeutic agent for treating AD, particularly at the early phases of the disease and especially in those in whom the relevant melatonin receptors are intact. As sleep deprivation has been shown to produce oxidative damage, impaired mitochondrial function, neurodegenerative inflammation, and altered proteosomal processing with abnormal activation of enzymes, treatment of sleep disturbances may be a priority for arresting the progression of AD. In this context the newly introduced melatonin agonist ramelteon can be of much therapeutic value because of its highly selective action on melatonin MT(1)/MT(2) receptors in promoting sleep.
format Text
id pubmed-3004402
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-30044022010-12-30 Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value Srinivasan, Venkatramanujam Kaur, Charanjit Pandi-Perumal, Seithikurippu Brown, Gregory M. Cardinali, Daniel P. Int J Alzheimers Dis Review Article Alzheimer's disease (AD) is an age-associated neurodegenerative disease characterized by the progressive loss of cognitive function, loss of memory and insomnia, and abnormal behavioral signs and symptoms. Among the various theories that have been put forth to explain the pathophysiology of AD, the oxidative stress induced by amyloid β-protein (Aβ) deposition has received great attention. Studies undertaken on postmortem brain samples of AD patients have consistently shown extensive lipid, protein, and DNA oxidation. Presence of abnormal tau protein, mitochondrial dysfunction, and protein hyperphosphorylation all have been demonstrated in neural tissues of AD patients. Moreover, AD patients exhibit severe sleep/wake disturbances and insomnia and these are associated with more rapid cognitive decline and memory impairment. On this basis, the successful management of AD patients requires an ideal drug that besides antagonizing Aβ-induced neurotoxicity could also correct the disturbed sleep-wake rhythm and improve sleep quality. Melatonin is an effective chronobiotic agent and has significant neuroprotective properties preventing Aβ-induced neurotoxic effects in a number of animal experimental models. Since melatonin levels in AD patients are greatly reduced, melatonin replacement has the potential value to be used as a therapeutic agent for treating AD, particularly at the early phases of the disease and especially in those in whom the relevant melatonin receptors are intact. As sleep deprivation has been shown to produce oxidative damage, impaired mitochondrial function, neurodegenerative inflammation, and altered proteosomal processing with abnormal activation of enzymes, treatment of sleep disturbances may be a priority for arresting the progression of AD. In this context the newly introduced melatonin agonist ramelteon can be of much therapeutic value because of its highly selective action on melatonin MT(1)/MT(2) receptors in promoting sleep. SAGE-Hindawi Access to Research 2010-12-08 /pmc/articles/PMC3004402/ /pubmed/21197086 http://dx.doi.org/10.4061/2011/741974 Text en Copyright © 2011 Venkatramanujam Srinivasan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Srinivasan, Venkatramanujam
Kaur, Charanjit
Pandi-Perumal, Seithikurippu
Brown, Gregory M.
Cardinali, Daniel P.
Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value
title Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value
title_full Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value
title_fullStr Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value
title_full_unstemmed Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value
title_short Melatonin and Its Agonist Ramelteon in Alzheimer's Disease: Possible Therapeutic Value
title_sort melatonin and its agonist ramelteon in alzheimer's disease: possible therapeutic value
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004402/
https://www.ncbi.nlm.nih.gov/pubmed/21197086
http://dx.doi.org/10.4061/2011/741974
work_keys_str_mv AT srinivasanvenkatramanujam melatoninanditsagonistramelteoninalzheimersdiseasepossibletherapeuticvalue
AT kaurcharanjit melatoninanditsagonistramelteoninalzheimersdiseasepossibletherapeuticvalue
AT pandiperumalseithikurippu melatoninanditsagonistramelteoninalzheimersdiseasepossibletherapeuticvalue
AT browngregorym melatoninanditsagonistramelteoninalzheimersdiseasepossibletherapeuticvalue
AT cardinalidanielp melatoninanditsagonistramelteoninalzheimersdiseasepossibletherapeuticvalue